What it is
Semaglutide is a GLP-1 receptor agonist, a prescription peptide medicine. It is studied and approved for specific uses, including type 2 diabetes and obesity. People know some brand versions as Ozempic and Wegovy. Show the Study does not prescribe it and does not supply it.
Studied for
- Type 2 diabetes, in large published randomized trials.
- Obesity, in large published randomized trials.
- Gut–brain incretin signaling, the pathway these trials are built on.
The evidence
Human trial. This is one of the few entries in the library with large, published randomized trials and measured outcomes. That is a different evidence tier from research peptides known mostly from animal work. A trial result is still not a personal recommendation.
What this page will not do
- Whether it fits a specific person is a decision with a licensed prescriber.
- Approved uses are specific. Use outside the label is a prescriber’s call, not a conclusion of this page.
- We do not give doses, cycling plans, or compounding instructions.
Still open
- How the published trade-offs apply to one person — a prescriber can walk through the current label.
- What long-term use and stopping look like in the literature your clinician relies on.
Educational content only. This page does not diagnose, treat, cure, or prevent anything, and it is not a dose. Talk with a licensed physician before starting, stopping, or changing any medication. Library reviewed November 2026.